Phenotypes associated with this allele

• Allele Symbol: Cry2^tm1Jhjh
• Allele Name: targeted mutation 1, Jan H J Hoeijmakers
• Allele ID: MGI:2181206
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cry2^tm1Jhjh/Cry2^tm1Jhjh	involves: 129P2/OlaHsd * C57BL/6	MGI:4943716
cx2	Cry2^tm1Jhjh/Cry2^tm1Jhjh Per2^tm1Brd/Per2^tm1Brd	involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6	MGI:3522463
cx3	Cry1^tm1Jhjh/Cry1^+ Cry2^tm1Jhjh/Cry2^tm1Jhjh	involves: 129P2/OlaHsd * C57BL/6	MGI:4943717
cx4	Cry1^tm1Jhjh/Cry1^tm1Jhjh Cry2^tm1Jhjh/Cry2^+	involves: 129P2/OlaHsd * C57BL/6	MGI:4943718
cx5	Cry1^tm1Jhjh/Cry1^tm1Jhjh Cry2^tm1Jhjh/Cry2^tm1Jhjh	involves: 129P2/OlaHsd * C57BL/6	MGI:4943719

Genotype
MGI:4943716

hm1

• Allelic Composition: Cry2^tm1Jhjh/Cry2^tm1Jhjh
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

skeleton

abnormal osteoclast physiology ( J:163112 )

• osteoclast activity is decreased compared to in wild-type mice

increased bone volume ( J:163112 )

behavior/neurological

prolonged circadian behavior period ( J:54241 )

• under dark:dark conditions

• however, light entrainment of locomotor activity is normal

immune system

abnormal osteoclast physiology ( J:163112 )

• osteoclast activity is decreased compared to in wild-type mice

hematopoietic system

abnormal osteoclast physiology ( J:163112 )

• osteoclast activity is decreased compared to in wild-type mice

Genotype
MGI:3522463

cx2

• Allelic Composition: Cry2^tm1Jhjh/Cry2^tm1Jhjh; Per2^tm1Brd/Per2^tm1Brd
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6

skeleton

decreased osteoblast cell number ( J:163112 )

decreased bone ossification ( J:163112 )

• mice exhibit decreased bone formation rate compared with wild-type mice

behavior/neurological

behavior/neurological phenotype ( J:79492 )

N • double homozygotes entrain to the LD cycle, displaying locomotor activity patterns similar to those of wild-type

N • unexpectedly, double homozygotes are able to maintain a circadian rhythm in DD (rescue of circadian rhythmicity)

N • profiles of cycling clock genes in the SCN indicate normal circadian behavior and core oscillator performance

Genotype
MGI:4943717

cx3

• Allelic Composition: Cry1^tm1Jhjh/Cry1⁺; Cry2^tm1Jhjh/Cry2^tm1Jhjh
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

behavior/neurological

abnormal circadian behavior period ( J:54241 )

• period is intermediate to single homozygotes

Genotype
MGI:4943718

cx4

• Allelic Composition: Cry1^tm1Jhjh/Cry1^tm1Jhjh; Cry2^tm1Jhjh/Cry2⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

behavior/neurological

abnormal circadian behavior ( J:54241 )

• under dark:dark conditions, mice exhibit a shorter free-running rhythm that gradually progresses into arrhythmicity unlike in wild-type mice

Genotype
MGI:4943719

cx5

• Allelic Composition: Cry1^tm1Jhjh/Cry1^tm1Jhjh; Cry2^tm1Jhjh/Cry2^tm1Jhjh
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

behavior/neurological

abnormal circadian behavior period ( J:54241 )

• following entrainment to a light:dark regime, mice abruptly adapt to a new situation by starting wheel running as soon as light is off and expanding their period of fragmented activity unlike wild-type mice

arrhythmic circadian behavior persistence ( J:54241 )

• under dark:dark conditions

• however, mice exhibit normal circadian rhythm under light:dark conditions

immune system

abnormal T cell activation ( J:159504 )

• mice exhibit an increase in activated T cells compared with wild-type mice

increased circulating interleukin-1 beta level ( J:159504 )

• following treatment with anti-CII antibodies

increased circulating interleukin-6 level ( J:159504 )

• following treatment with anti-CII antibodies

• however, treatment with anti-TNF-alpha antibodies reduces serum levels of IL6 induced by anti-CII antibodies

increased circulating tumor necrosis factor level ( J:159504 )

• following treatment with anti-CII antibodies

• however, treatment with anti-TNF-alpha antibodies reduces serum levels of TNF-alpha induced by anti-CII antibodies

increased tumor necrosis factor secretion ( J:159504 )

• in splenocyte

increased susceptibility to induced arthritis ( J:159504 )

• following treatment with anti-CII antibodies, mice exhibit increased arthritis score and serum levels of TNF-alpha, IL1beta, IL6, and MMP3 compared with wild-type mice

• however, treatment with anti-TNF-alpha antibodies reduces induced arthritis score and levels of TNF-alpha, IL6, and MMP3

skeleton

increased susceptibility to induced arthritis ( J:159504 )

• following treatment with anti-CII antibodies, mice exhibit increased arthritis score and serum levels of TNF-alpha, IL1beta, IL6, and MMP3 compared with wild-type mice

• however, treatment with anti-TNF-alpha antibodies reduces induced arthritis score and levels of TNF-alpha, IL6, and MMP3

homeostasis/metabolism

increased circulating interleukin-1 beta level ( J:159504 )

• following treatment with anti-CII antibodies

increased circulating interleukin-6 level ( J:159504 )

• however, treatment with anti-TNF-alpha antibodies reduces serum levels of IL6 induced by anti-CII antibodies

• following treatment with anti-CII antibodies

increased circulating tumor necrosis factor level ( J:159504 )

• following treatment with anti-CII antibodies

• however, treatment with anti-TNF-alpha antibodies reduces serum levels of TNF-alpha induced by anti-CII antibodies

hematopoietic system

abnormal T cell activation ( J:159504 )

• mice exhibit an increase in activated T cells compared with wild-type mice